Endoscopic mucosal resection for Barrett’s neoplasia: Long-term outcomes from the largest Canadian single-center experience
Endoscopy International Open · 17.06.2025 · 13 (CP)
DOI: 10.1055/a-2602-8961 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy International Open, erschienen am 17.06.2025. Verfasst von Yusuke Fujiyoshi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Endoscopic mucosal resection (EMR) remains an important treatment for high-grade dysplasia (HGD) and early esophageal adenocarcinoma (EAC) in Barrett’s esophagus (BE). However, there are limited data regarding long-term recurrence rates. This study aimed to investigate the neoplasia recurrence rate following EMR with long-term follow-up. This was a retrospective cohort study at a tertiary-referral center in Canada. Patients with Barrett’s neoplasia (HGD/EAC) treated with EMR between January 2001 and December 2023 were included. The primary outcome was long-term neoplasia recurrence rate after complete remission of neoplasia (CRN). Secondary outcomes were residual/metachronous neoplasia rate at first follow-up, CRN rate, and long-term rate of patients successfully managed by endoscopy. A total of 552 patients (83.7% male, mean age 66.3 years) were included (HGD: 22.5%, EAC: 77.5%). After EMR, 475 patients were deemed to have had successful endoscopic resection (low lymph-node metastasis risk with tumor-free deep margin), 455 of whom underwent surveillance follow-up. At first follow-up, residual/metachronous neoplasia was observed in 20.9% (95/455), but 95.6% (435/455) eventually achieved CRN after undergoing a median of two EMR sessions (interquartile range: 1–4). As a primary outcome, the 5-year neoplasia recurrence rate was 10.5%, the 10-year rate was 21.6%, and the 15-year rate was 34.9%. During surveillance, neoplasia recurrence was observed in 38 patients, but 68.4% of them (26/38) were managed with endoscopic therapy. The overall rate of patients successfully managed by endoscopy was 93.0% (423/455). While the success rate of EMR for BE is excellent, this study highlights substantial long-term risk of neoplastic recurrence, underscoring the need for indefinite surveillance for patients who had HGD or EAC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
- Department of Medicine, Division of Gastroenterology, University of Ottawa, Ottowa Hospital Research Institute, Ottawa, ON, Canada.
- Department of Laboratory Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
ORCID-Profile: Yusuke Fujiyoshi, Kareem Khalaf, Mary Raina Angeli Fujiyoshi, Natalia C Calo
Zitieren
APA
Fujiyoshi, Y., Khalaf, K., Tham, D., Fujiyoshi, M. R. A., Streutker, C. J., Calo, N. C., Mosko, J. D., May, G. R., Marcon, N. E., & Teshima, C. W. (2025). Endoscopic mucosal resection for Barrett’s neoplasia: Long-term outcomes from the largest Canadian single-center experience. Endoscopy International Open, 13(CP). https://doi.org/10.1055/a-2602-8961
Vancouver
Fujiyoshi Y, Khalaf K, Tham D, Fujiyoshi MRA, Streutker CJ, Calo NC, et al. Endoscopic mucosal resection for Barrett’s neoplasia: Long-term outcomes from the largest Canadian single-center experience. Endoscopy International Open. 2025;13(CP). doi:10.1055/a-2602-8961
BibTeX
@article{Fujiyoshi2025,
author = {Fujiyoshi, Yusuke and Khalaf, Kareem and Tham, Daniel and Fujiyoshi, Mary Raina Angeli and Streutker, Catherine J and Calo, Natalia C and Mosko, Jeffrey D and May, Gary R and Marcon, Norman E and Teshima, Christopher W},
title = {Endoscopic mucosal resection for Barrett’s neoplasia: Long-term outcomes from the largest Canadian single-center experience},
journal = {Endoscopy International Open},
year = {2025},
volume = {13},
number = {CP},
doi = {10.1055/a-2602-8961}
}
EUVIMED